- Home
- GDO vs SERA Comparison
GDO vs SERA Comparison
Compare GDO & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDO
- SERA
- Stock Information
- Founded
- GDO 2009
- SERA 2008
- Country
- GDO United States
- SERA United States
- Employees
- GDO N/A
- SERA N/A
- Industry
- GDO Finance Companies
- SERA Precision Instruments
- Sector
- GDO Finance
- SERA Health Care
- Exchange
- GDO Nasdaq
- SERA Nasdaq
- Market Cap
- GDO 86.3M
- SERA 70.4M
- IPO Year
- GDO N/A
- SERA 2021
- Fundamental
- Price
- GDO $11.71
- SERA $2.77
- Analyst Decision
- GDO
- SERA
- Analyst Count
- GDO 0
- SERA 0
- Target Price
- GDO N/A
- SERA N/A
- AVG Volume (30 Days)
- GDO 39.4K
- SERA 763.6K
- Earning Date
- GDO 01-01-0001
- SERA 08-06-2025
- Dividend Yield
- GDO 9.81%
- SERA N/A
- EPS Growth
- GDO N/A
- SERA N/A
- EPS
- GDO N/A
- SERA N/A
- Revenue
- GDO N/A
- SERA $115,000.00
- Revenue This Year
- GDO N/A
- SERA $390.13
- Revenue Next Year
- GDO N/A
- SERA $440.54
- P/E Ratio
- GDO N/A
- SERA N/A
- Revenue Growth
- GDO N/A
- SERA N/A
- 52 Week Low
- GDO $11.21
- SERA $1.37
- 52 Week High
- GDO $13.04
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- GDO 62.04
- SERA 55.77
- Support Level
- GDO $11.70
- SERA $2.34
- Resistance Level
- GDO $11.83
- SERA $2.80
- Average True Range (ATR)
- GDO 0.09
- SERA 0.37
- MACD
- GDO -0.00
- SERA 0.05
- Stochastic Oscillator
- GDO 63.27
- SERA 37.00
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.